GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List

Range Low Price High Price Comment
30 days $0.87 $1.65 Thursday, 18th Apr 2024 ADAP stock ended at $0.90. This is 8.98% less than the trading day before Wednesday, 17th Apr 2024. During the day the stock fluctuated 13.44% from a day low at $0.87 to a day high of $0.99.
90 days $0.691 $2.05
52 weeks $0.420 $2.05

Historical Adaptimmune Therapeutics plc prices

Date Open High Low Close Volume
2024-03-13 $1.56 $1.70 $1.48 $1.59 1 395 812
2024-03-12 $1.54 $1.55 $1.42 $1.49 1 610 959
2024-03-11 $1.80 $1.80 $1.53 $1.54 2 086 121
2024-03-08 $1.79 $2.05 $1.72 $1.75 11 995 713
2024-03-07 $1.75 $1.85 $1.62 $1.74 2 524 115
2024-03-06 $1.59 $1.75 $1.49 $1.71 2 202 397
2024-03-05 $1.48 $1.53 $1.38 $1.46 813 347
2024-03-04 $1.63 $1.64 $1.42 $1.48 1 116 993
2024-03-01 $1.56 $1.64 $1.55 $1.59 920 841
2024-02-29 $1.61 $1.61 $1.51 $1.57 1 532 994
2024-02-28 $1.77 $1.77 $1.50 $1.61 1 707 842
2024-02-27 $1.69 $1.79 $1.60 $1.71 2 182 338
2024-02-26 $1.50 $1.64 $1.43 $1.64 1 659 015
2024-02-23 $1.45 $1.50 $1.38 $1.48 807 851
2024-02-22 $1.53 $1.64 $1.38 $1.38 1 976 169
2024-02-21 $1.23 $1.57 $1.23 $1.50 2 809 572
2024-02-20 $1.18 $1.32 $1.18 $1.26 1 085 016
2024-02-16 $1.25 $1.28 $1.18 $1.20 786 588
2024-02-15 $1.32 $1.32 $1.22 $1.25 667 398
2024-02-14 $1.25 $1.32 $1.20 $1.28 732 073
2024-02-13 $1.16 $1.29 $1.15 $1.20 1 061 027
2024-02-12 $1.26 $1.28 $1.19 $1.21 1 088 100
2024-02-09 $1.24 $1.33 $1.20 $1.25 1 484 063
2024-02-08 $1.27 $1.27 $1.12 $1.15 1 570 831
2024-02-07 $1.32 $1.42 $1.21 $1.24 2 143 763
Click to get the best stock tips daily for free!

About Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposa... ADAP Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT